Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck (Q34287207)
scientific article
Language:
Current Data About Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck
(P31) (Q13442814)
(P248)
(P698) 14701768
(P813) Tuesday, August 1, 2017

(P50) (Q37392552)
(P1932) Manuel Hidalgo
(P1545) 4

(Q73567428)
(P1545) 3
(P1932) Everett E Vokes
(P248)
(P698) 14701768
(P813) Tuesday, August 1, 2017

(Q92127474)
(P1545) 6
(P1932) Lillian L Siu
(P248)
(P698) 14701768
(P813) Tuesday, August 1, 2017

(P304) 77-85
(P248)
(P698) 14701768
(P813) Tuesday, August 1, 2017

(P407) (Q1860)

(P433) 1
(P248)
(P698) 14701768
(P813) Tuesday, August 1, 2017

(P478) 22
(P248)
(P698) 14701768
(P813) Tuesday, August 1, 2017

(P577) Thursday, January 1, 2004
(P248)
(P698) 14701768
(P813) Tuesday, August 1, 2017

(P921) (Q6934595)

(Q181600)

(Q418369)
(P887)

(P1433) (Q400292)
(P248)
(P698) 14701768
(P813) Tuesday, August 1, 2017

(P1476) "Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck" (language: en)
(P248)
(P698) 14701768
(P813) Tuesday, August 1, 2017

(P2093) Denis Soulieres
(P1545) 1
(P248)
(P698) 14701768
(P813) Tuesday, August 1, 2017

Neil N Senzer
(P1545) 2
(P248)
(P698) 14701768
(P813) Tuesday, August 1, 2017

Sanjiv S Agarwala
(P1545) 5
(P248)
(P698) 14701768
(P813) Tuesday, August 1, 2017

other details